XL147 (SAR245408) is a novel small molecule PI3K inhibitor. Activation of the PI3 kinase pathway occurs frequently in many cancers and is implicated in tumor cell proliferation, survival, and resistance to chemotherapy and radiotherapy. XL147 demonstrated cytotoxic activity, with a median relative IC(50) value of 10.9 µM (range 2.7-24.5 µM) in vitro. Also XL147 was well tolerated in vivo, all 44 tested xenograft models were evaluable for efficacy. XL147 (SAR245408) induced tumor growth inhibition meeting criteria for intermediate EFS T/C activity (EFS T/C > 2) in 4 of 37 (11%) solid tumor xenografts. Knockdown of HER3 with siRNA or cotreatment with the HER2 inhibitors trastuzumab or lapatinib enhanced XL147-induced cell death and inhibition of pAKT and pS6 in HER2(+) cells. Trastuzumab and lapatinib each synergized with XL147 for inhibition of pAKT and growth of established BT474 xenografts.
|Cell lines||panel of cell lines, such as BT474, PC-3 and MCF-7|
|Preparation method||Cell-based assays.
Cell lines were obtained from the ATCC in 2001–2005 and maintained in culture conditions at 37°C under 5% CO2 as previously described. For PI3K pathway status assessment following EGF treatment, the culture medium was replaced with test compounds dissolved in serum-free DMEM containing 0.3% DMSO. After incubation for 3 hours, cells were stimulated with 100 ng/mL of EGF (R&D Systems, 236-EG) for 10 minutes and Western immunoblot analysis of cell lysates was performed as previously described. Assessment of mTOR pathway status in Ramos cells was performed as previously described. Cellular proliferation was assessed as previously described using the Cell Proliferation ELISA, bromodeoxyuridine (BrdUrd) chemiluminescence kit.
|Incubation time||48 or 72 h|
|Animal models||MCF-7 and OVCAR cells tumour xenograft model|
|Formulation||sterile water/10 mmol/L HCl or water|
|Dosages||30, 100mg/kg qd or 300mg/kg twice weekly|
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 80 mg/mL|
The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models.
Foster P, et al. Mol Cancer Ther. 2015 Apr;14(4):931-40. PMID: 25637314.
|Related PI3K Products|
SF2523 is a highly selective and potent inhibitor of PI3K with IC50 values of 34 nM, 158 nM, 9 nM, 241 nM and 280 nM for PI3Kα, PI3Kγ, DNA-PK, BRD4 and mTOR, respectively.
IPI549 is a potent and selective PI3Kγ Inhibitor with IC50 of 16 nM.
Vps34-IN1 is a potent and highly selective Vps34 inhibitor with IC50 of 25 nM invitro,which does not significantly inhibit the isoforms of class I as well as class II PI3Ks.
Voxtalisib (SAR245409, XL765) Analogue is a dual inhibitor of mTOR/PI3K, mostly for p110γ with IC50 of 9 nM; also inhibits DNA-PK and mTOR. Phase 1/2.
PI-3065 is a novel potent and selective PI3K p110δ inhibitor with IC50 of 15 nM; exhibits > 100 fold selectivity against p110α, p110β, p110γ, DNA-PK and mTOR
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.